Navigation Links
Neurochem announces departure of two members of management team
Date:2/21/2008

LAVAL, QC, Feb. 21 /PRNewswire-FirstCall/ - In light of Neurochem Inc.'s (NASDAQ: NRMX; TSX: NRM) new strategic direction, the Company announces the departure, effective February 21, 2008, of two members of its senior management team, Dr. Andreas Orfanos, MBB. Ch, MBA, Executive Vice President, Strategic Planning and Scientific Affairs, and Ms. Christine Lennon, MBA, Vice President, Business Development. The possibility of their acting as consultants in respect of specific projects is being explored.

"On behalf of the Board of Directors and my colleagues, I want to express our gratitude to Dr. Orfanos and Ms. Lennon for their dedication and valuable contribution to Neurochem. We wish them every success in the future," said Dr. Francesco Bellini, Neurochem's Chairman, President and CEO.

About Neurochem

Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at http://www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the Neurochem group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of Neurochem Inc. for further risk factors that might affect the Neurochem group and its business.

Lise Hebert, PhD, Vice President, Corporate Communications, (450) 680-4572, lhebert@neurochem.com


'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
2. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
3. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
4. Neurochem to present at JPMorgan Healthcare Conference
5. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
6. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
7. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
8. Neurochem reports results for third quarter of fiscal 2007
9. Emergency Dentist 24/7(TM) Announces Worldwide Licensing Program
10. LCA-Vision Announces Quarterly Dividend Payment
11. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Coast Dental ... February is National Children’s Dental Health Month and family dentist Yvonne Dorrian, DMD, is ... at Coast Dental , located next to Target at 1207 North Peachtree Parkway ...
(Date:2/8/2016)... New York, NY (PRWEB) , ... February 08, 2016 , ... ... handles are too much to handle, you are not alone. According to the Center ... conditions include heart disease, stroke, type 2 diabetes and certain types of cancer, some ...
(Date:2/8/2016)... ... 2016 , ... Delta Dental of California and its affiliated companies announced today ... Radine, who recently retired as president and CEO of Delta Dental of California and ... the Year , helped lead the effort to raise funds for studies to strengthen ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain ... 1,400 booths and 700 companies. Attendees also get to see the most incredible ... Garden & Home Show , at the Colorado Convention Center - 700 14th St. ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering ... 2016 in honor of his birthday on February 10th. During this time, people ... is known by over 250,000 people from over 40 different countries as an “ordinary ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016  Echo ... medical device company focused on non-invasive continuous ... announced today announced that it will host ... February 17, 2015 at 9:00 a.m. Eastern ... discuss its corporate strategy, advancements in its ...
(Date:2/8/2016)... Feb. 8, 2016 Nueterra, the ... specialized in the development of equity partnerships ... it has divided its interests between two ... Capital will continue the founding company,s private ... operate a national system of integrated provider ...
(Date:2/8/2016)... Intarcia Therapeutics, Inc. today announced the appointment of ... created role of Vice President, Head of Global Medical ... of leadership experience at leading pharmaceutical, biotechnology, and health ... Most recently Dr. Yee served as VP, Head of ... Officer at AstraZeneca, where he led medical affairs across ...
Breaking Medicine Technology: